Most women are told the same thing: estrogen drops at menopause, and that's why vaginal dryness happens.

That's true as far as it goes. But it doesn't explain why some women sail through the transition with minimal symptoms while others experience progressive dryness, irritation, and discomfort that worsens over years, even on estrogen therapy.

The difference lies in two things medicine rarely discusses: what the adrenal glands are doing after the ovaries step back, and how well individual tissue can adapt to a changed hormonal environment.

After menopause, the ovaries dramatically reduce their output of estrogen and androgens, hormones that maintain vaginal epithelial thickness, moisture retention, blood flow, and elasticity. That loss sets a new baseline for every woman. But it doesn't determine where she ends up.

What determines her experience is whether her adrenal glands are producing adequate DHEA — the precursor molecule that vaginal and vulvar tissue can convert locally into both estrogens and androgens — and whether her tissue retains the metabolic capacity to use it.

Hormone Loss Is the Starting Point

Estrogen and androgens support vaginal tissue by:

• sustaining epithelial thickness

• supporting vascular tone and perfusion

• maintaining moisture dynamics

• modulating tissue sensitivity

When ovarian hormone production declines, vaginal tissue enters a new physiological state. Without this hormonal shift, the downstream changes described on this page would not occur.

Hormone loss is the trigger.

However, hormone loss alone does not determine how severe, persistent, or disruptive dryness becomes. That experience is shaped by how multiple tissue-support systems respond once hormonal support is reduced.

Vaginal Tissue Responds Locally to Hormone Loss

Vaginal and vulvar tissues do not rely solely on circulating hormones, but instead depend on intracrine signaling—the local conversion of adrenal precursors such as DHEA into active estrogens and androgens within the tissue itself. [3,4]

This process—known as intracrine hormone signaling—helps determine how much hormonal activity vaginal tissue can sustain after ovarian production declines. [3] When local signaling capacity diminishes, moisture retention and tissue resilience may decrease even when some systemic hormone exposure remains.  Luckily our bodies retain this local ability well past menopause. This tells us that we do not need systemic hormone treatments to improve our vulvovaginal wellness - in fact, often systemic treatments do not solve for this issue. 

This mechanism is explained in detail in intracrine hormone signaling in vaginal and vulvar tissue. Here, it represents the first major determinant of how hormone loss is experienced locally.

What is greatly overlooked is how differently each woman’s adrenal system responds to stress over time. After menopause, adrenal-derived DHEA and DHEA-S become the primary systemic precursors for local sex steroid synthesis in peripheral tissues, including vaginal and vulvar epithelium. [3,8]  This tissue relies on DHEA availability for local repair and regeneration.

When stress is chronic, DHEA production may be reduced,[8] potentially limiting the substrate available for local hormone synthesis and tissue repair.  This limits the hormone substrate vaginal tissue depends on to maintain moisture, elasticity, and resilience — even when estrogen is present.

As a result, tissue signaling may still occur, but the biology required to complete repair is no longer fully available. This helps explain why dryness and discomfort can persist, plateau, or vary widely between women during midlife.

For a broader view of how DHEA functions across the body, see DHEA benefits for women.

DHEA/DHEA-S are the dominant systemic precursors 

• Adrenal DHEA-S is the principal circulating reservoir for vaginal/vulvar hormone creation.

• These tissues convert DHEA → androstenedione → testosterone / DHT → estradiol [3,8] 

• This allows:

  • tissue-specific regulation of estradiol and testosterone

  • avoidance of systemic hormone excess

In postmenopausal women:

All sex steroids are formed locally in peripheral tissues from adrenal precursors.

This includes vaginal and vulvar tissue.

This is why managing stress into midlife is vital to maintain vulvovaginal health. 

For a deeper understanding of how DHEA supports tissue signaling and sexual function, see DHEA and libido in women.

Inflammation Shapes How Dryness Is Felt

Following hormone loss, low-grade inflammation becomes a more influential determinant of tissue behavior, contributing to impaired epithelial renewal, extracellular matrix disruption, and increased sensory sensitivity. [1,9] 

Inflammatory signaling can [5,7,9]

• disrupt epithelial renewal

• alter extracellular matrix structure

• increase sensory nerve exposure

• interfere with moisture retention  

In this context, dryness may feel irritated, reactive, or uncomfortable rather than simply dry. Importantly, inflammatory tone is often systemic, meaning vaginal tissue reflects changes occurring elsewhere in the body.

Hormone loss lowers the threshold at which inflammation affects tissue experience.

Vascular Support Becomes a Limiting Factor

Estrogen and androgens support vascular tone and microcirculation.[6]  As hormonal support declines, reduced vascular tone and microcirculatory perfusion become key limiting factors in oxygen delivery, nutrient supply, and tissue hydration.

Adequate perfusion is required for:

• oxygen delivery

• nutrient transport

• tissue hydration

• secretory function

Subtle changes in vascular function—common in midlife—may disproportionately affect vaginal tissue, which is highly sensitive to perfusion. In this setting, dryness can be understood as an early signal of reduced tissue supply, not simply surface dehydration.

Metabolic Capacity Influences Tissue Renewal

Vaginal epithelium is a renewing tissue. Its ability to maintain structure and hydration depends on cellular energy availability and metabolic efficiency.

After hormone loss, metabolic constraints such as [1] :

• reduced mitochondrial efficiency

• altered glucose handling

• increased glycation

can slow epithelial turnover and affect collagen structure. When renewal capacity declines, dryness may persist even when surface moisture is temporarily increased.

This helps explain why dryness often correlates with broader changes in energy, recovery, or metabolic resilience during midlife.

Nervous System Regulation Modulates Moisture and Sensation

Hormones interact closely with autonomic nervous system regulation.[7]  As hormonal support declines, vaginal tissue becomes more sensitive to changes in neural signaling.

Sympathetic dominance or chronic stress can:

• reduce local blood flow

• suppress secretory activity

• heighten sensory awareness

Vaginal dryness often fluctuates with stress, illness, and sleep disruption, reflecting autonomic regulation of blood flow, secretion, and sensory signaling within the tissue. [7] 

Why Estrogen Alone May Not Fully Resolve Dryness

Estrogen remains a foundational signal for vaginal tissue, but does not independently restore intracrine capacity, inflammatory balance, vascular function, metabolic renewal or neural regulation. [2,3] 

This explains why estrogen isn’t enough for midlife vaginal tissue health for some women. Estrogen addresses the initiating deficit, but tissue experience depends on whether downstream systems can respond.

How GSM Fits Into This Framework

Genitourinary syndrome of menopause (GSM) describes the constellation of vulvovaginal and urinary symptoms that arise from the combined effects of hormone loss and downstream changes in tissue structure, signaling, and function. [1,2]  

From a biological perspective, GSM reflects:

• hormone loss as the initiating event

• combined constraints across tissue-support systems

• cumulative effects on structure, moisture, and sensation

Dryness is often the earliest and most persistent expression of this convergence. A clinical translation of this framework is explored in Understanding Genitourinary Syndrome of Menopause (GSM).

Dryness as Tissue Information

When vaginal dryness persists, it is often treated as a problem to override. From a systems perspective, it is more accurately understood as information about tissue context following hormone loss.

Vaginal dryness reflects the integrated state of tissue support—how effectively the tissue is hormonally supplied, locally regulated, structurally maintained, and metabolically renewed.

This in turn suggests that metabolic state - availability of nutrients, inflammation, hydration - will all influence our vulvovaginal health. 

A key determinant of vulvovaginal tissue function in midlife is the availability of DHEA production from your adrenal glands.  If you are managing stress well, your adrenals will function to create DHEA well into older age. If instead you produce primarily cortisol from unmanaged stress, you may produce less DHEA which will directly impact your vulvovaginal wellness and experience. 

How This Page Fits Into the Larger Picture

This page looks at vaginal dryness as a modifiable biological signal, not an isolated symptom.

Other educational pages explore related layers of the same system — including local hormone signaling, tissue responsiveness, and the broader framework used to describe midlife genital changes. Each adds context rather than replacing what’s covered here.

From here, you may wish to explore:

• Intracrine Hormone Signaling in Vaginal and Vulvar Tissue

• Why Estrogen Isn’t Enough for Midlife Vaginal Tissue Health

• Understanding Genitourinary Syndrome of Menopause (GSM)

Each page examines a different layer of the same biological system.

Educational Note

The information on this page is provided for educational purposes only and is not intended to diagnose, treat, cure, or prevent any medical condition.

Cited scientific sources:

1. Faubion SS, Larkin LC, Stuenkel CA, et al. Management of genitourinary syndrome of menopause in women: a clinical review. Mayo Clin Proc. 2017;92(12):1842–1849. doi:10.1016/j.mayocp.2017.08.022
2. The North American Menopause Society (NAMS). The 2020 genitourinary syndrome of menopause position statement. Menopause. 2020;27(9):976–992. doi:10.1097/GME.0000000000001609
3. Labrie F. Intracrinology in action: importance of extragonadal sex steroid biosynthesis and inactivation in peripheral tissues. Menopause. 2017;24(9):1027–1039. doi:10.1097/GME.0000000000000907
4. Labrie F, Archer DF, Koltun W, et al. Effect of intravaginal dehydroepiandrosterone (prasterone) on vaginal atrophy. Menopause. 2015;22(12):1289–1303. doi:10.1097/GME.0000000000000467
5. Palacios S, Cancelo MJ. Clinical update on genitourinary syndrome of menopause: a review. Maturitas. 2016;83:5–10. doi:10.1016/j.maturitas.2015.10.008
6. Calleja-Agius J, Brincat MP. The urogenital system and the menopause. Climacteric. 2009;12(4):279–285. doi:10.1080/13697130902955774
7. Goldstein AT, Burrows LJ, Goldstein SW. Vulvar and vaginal atrophy: physiology and clinical implications. J Sex Med. 2010;7(2 Pt 2):849–856. doi:10.1111/j.1743-6109.2009.01630.x
8. Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev. 2011;32(1):81–151. doi:10.1210/er.2010-0013
9. Straub RH. The complex role of estrogens in inflammation. Endocr Rev. 2007;28(5):521–574. doi:10.1210/er.2007-0001